搜索结果：Current pharmaceutical biotechnology

Biotechnology Industry 5.0 is advancing with the integration of cutting-edge technologies like Machine Learning (ML), the Internet Of Things (IoT), and cloud computing. It is no surprise that an industry that utilizes data from customers and can alter their lives is a target of a variety of attacks. This chapter provides a perspective of how Machine Learning Security Operations (MLSecOps) can help secure the biotechnology Industry 5.0. The chapter provides an analysis of the threats in the biotechnology Industry 5.0 and how ML algorithms can help secure with industry best practices. This chapter explores the scope of MLSecOps in the biotechnology Industry 5.0, highlighting how crucial it is to comply with current regulatory frameworks. With biotechnology Industry 5.0 developing innovative solutions in healthcare, supply chain management, biomanufacturing, pharmaceuticals sectors, and more, the chapter also discusses the MLSecOps best practices that industry and enterprises should follow while also considering ethical responsibilities. Overall, the chapter provides a discussion of how to integrate MLSecOps into the design, deployment, and regulation of the processes in biotechnology

The escalating cost, extended timelines, and low success rates in pharmaceutical research demand a fundamental rethinking of biotechnology R&D infrastructure. This chapter introduces the concept of the AI-Integrated Biotechnology Hub, a purpose-built research ecosystem uniting residential, commercial, clinical, and research facilities under a central, AI-driven operating system. Designed as a multi-sided platform, the hub leverages continuous, multi-modal health data collection, advanced smart living environments, and federated learning models to enable secure, privacy-preserving biomedical research. By integrating real estate, biotechnology facilities, research hospitals, and community services, the model maximizes data utility, accelerates drug discovery, and enhances resident well-being. Transparency, accountability, and ethical stewardship are critical pillars of governance, enacted through dynamic consent, data trusts, and multi-stakeholder oversight. Scalable across urban and vertical architectures, this paradigm offers a viable, sustainable pathway toward improving healthspan, fostering innovation, and reshaping the economics of global drug development.

The pharmaceutical supply chain faces escalating cybersecurity challenges threatening patient safety and operational continuity. This paper examines the transformative potential of zero trust architecture for enhancing security and resilience within this critical ecosystem. We explore the challenges posed by data breaches, counterfeiting, and disruptions and introduce the principles of continuous verification, least-privilege access, and data-centric security inherent in zero trust. Real-world case studies illustrate successful implementations. Benefits include heightened security, data protection, and adaptable resilience. As recognized by researchers and industrialists, a reliable drug tracing system is crucial for ensuring drug safety throughout the pharmaceutical production process. One of the most pivotal domains within the pharmaceutical industry and its associated supply chains where zero trust can be effectively implemented is in the management of narcotics, high-health-risk drugs, and abusable substances. By embracing zero trust, the pharmaceutical industry fortifies its supply chain against constantly changing cyber threats, ensuring the trustworthiness of critical medica

There are significant differences in innovation performance between countries. Additionally, the pharmaceutical sector is stronger in some countries than in others. This suggests that the development of the pharmaceutical industry can influence a country's innovation performance. Using the Global Innovation Index and selected performance measures of the pharmaceutical sector, this study examines how the pharmaceutical sector influences the innovation performance of countries from the European context. The dataset of 27 European countries was analysed using simple, and multiple linear regressions and Pearson correlation. Our findings show that only three indicators of the pharmaceutical industry, more precisely pharmaceutical Research and Development, pharmaceutical exports, and pharmaceutical employment explain the innovation performance of a country largely. Pharmaceutical Research and Development and exports have a significant positive impact on a country's innovation performance, whereas employment in the pharmaceutical industry has a slightly negative impact. Additionally, global innovation performance has been found to positively influence life expectancy. We further outline t

Research and Development is the largest budget position in the pharmaceutical industry, with clinical trials being a critical, yet costly and time-consuming component to inform decisions. Beyond drug efficacy, the probability of success and efficiency of research and development are highly dependent on the approaches used for designing, analyzing, and interpreting clinical trials. Deep understanding of statistical methodology and quantitative approaches is therefore essential. Consequently, dedicated methodology groups have emerged in mid-size and large pharmaceutical companies and CROs. Their remit is to lead the conception and implementation of innovative quantitative methodologies in order to improve drug development, often by addressing complexities or offering more efficient designs. To achieve this, they collaborate internally and externally (e.g., with academics, regulators) to identify common challenges and tear down silos in order to invest in methods with the highest impact on efficiency and value to the portfolio. Given the immense financial stakes of drug development -- where delays carry massive implications -- these groups represent a critical strategic investment. Ho

We present a Japanese domain-specific language model for the pharmaceutical field, developed through continual pretraining on 2 billion Japanese pharmaceutical tokens and 8 billion English biomedical tokens. To enable rigorous evaluation, we introduce three new benchmarks: YakugakuQA, based on national pharmacist licensing exams; NayoseQA, which tests cross-lingual synonym and terminology normalization; and SogoCheck, a novel task designed to assess consistency reasoning between paired statements. We evaluate our model against both open-source medical LLMs and commercial models, including GPT-4o. Results show that our domain-specific model outperforms existing open models and achieves competitive performance with commercial ones, particularly on terminology-heavy and knowledge-based tasks. Interestingly, even GPT-4o performs poorly on SogoCheck, suggesting that cross-sentence consistency reasoning remains an open challenge. Our benchmark suite offers a broader diagnostic lens for pharmaceutical NLP, covering factual recall, lexical variation, and logical consistency. This work demonstrates the feasibility of building practical, secure, and cost-effective language models for Japanes

The present study considers the rural pharmaceutical retail sector in India, where the arrival of organized retailers and e-retailers is testing the survival strategies of unorganized retailers. Grounded in a field investigation of the Indian pharmaceutical retail sector, this study integrates primary data collection, consumer conjoint analysis and design of experiments to develop an empirically grounded agent-based simulation of multi-channel competition among unorganized, organized and e-pharmaceutical retailers. The results of the conjoint analysis reveal that store attributes of price discount, quality of products offered, variety of assortment, and degree of personalized service, and customer attributes of distance, degree of mobility, and degree of emergency are key determinants of optimal store choice strategies. The primary insight obtained from the agent-based modeling is that the attribute levels of each individual retailer have some effect on other retailers performance. The field-calibrated simulation also evidenced counterintuitive behavior that an increase in unorganized price discounts initially leads to an increase in average footprint at unorganized retailers, but

The survival of unorganized pharmacies is increasingly challenging in the face of growing competition from organized and e-pharmaceutical retail channels in emerging economies. A theoretical model is developed to capture the triple-channel interactions among unorganized, organized and e-retailing in emerging markets, taking into account the essential features of the pharmaceutical retail landscape, consumers, retailers and pharmaceutical products. Given the retailer and customer-specific factors, the price-setting game between the triple-channel retailers yielded the optimal prices for these retailers. The analysis found that the product category level demand has no influence on optimal pricing strategies of the retailers. The analysis also reveals counterintuitive results, for instance, (i) an increase in customer acceptance of unorganized retailers will result in a decrease in profits of both unorganized and organized retailers; (ii) as the distance and transportation cost to unorganized retailers increases for the consumers, the profit of the unorganized retailer increases; and (iii) consumers marginal utility of money has no influence on the optimal price, but have an influence

Pharmaceutical research and development has accumulated vast and heterogeneous archives of data. Much of this knowledge stems from discontinued programs, and reusing these archives is invaluable for reverse translation. However, in practice, such reuse is often infeasible. In this work, we introduce DiscoVerse, a multi-agent co-scientist designed to support pharmaceutical research and development at Roche. Designed as a human-in-the-loop assistant, DiscoVerse enables domain-specific queries by delivering evidence-based answers: it retrieves relevant data, links across documents, summarises key findings and preserves institutional memory. We assess DiscoVerse through expert evaluation of source-linked outputs. Our evaluation spans a selected subset of 180 molecules from Roche's research and development repositories, encompassing over 0.87 billion BPE tokens and more than four decades of research. To our knowledge, this represents the first agentic framework to be systematically assessed on real pharmaceutical data for reverse translation, enabled by authorized access to confidential archives covering the full lifecycle of drug development. Our contributions include: role-specialized

The pharmaceutical industry has witnessed exponential growth in transforming operations towards continuous manufacturing to effectively achieve increased profitability, reduced waste, and extended product range. Model Predictive Control (MPC) can be applied for enabling this vision, in providing superior regulation of critical quality attributes. For MPC, obtaining a workable model is of fundamental importance, especially in the presence of complex reaction kinetics and process dynamics. Whilst physics-based models are desirable, it is not always practical to obtain one effective and fit-for-purpose model. Instead, within industry, data-driven system-identification approaches have been found to be useful and widely deployed in MPC solutions. In this work, we demonstrated the applicability of Recurrent Neural Networks (RNNs) for MPC applications in continuous pharmaceutical manufacturing. We have shown that RNNs are especially well-suited for modeling dynamical systems due to their mathematical structure and satisfactory closed-loop control performance can be yielded for MPC in continuous pharmaceutical manufacturing.

Many pharmaceutical companies face concerns with the maintenance of desired revenue levels. Sales forecasts for the current portfolio of products and projects may indicate a decline in revenue as the marketed products approach patent expiry. To counteract the potential downturn in revenue, and to establish revenue growth, an in-flow of new projects into the development phases is required. In this article, we devise an approach with which the in-flow of new projects could be optimized, while adhering to the objectives and constraints set on revenue targets, budget limitations and strategic considerations on the composition of the company's portfolio.

Data scarcity in pharmaceutical research has led to reliance on labour-intensive trial-and-error approaches for development rather than data-driven methods. While Machine Learning offers a solution, existing datasets are often small and noisy, limiting their utility. To address this, we developed a Variationally Encoded Conditional Tabular Generative Adversarial Network (VECT-GAN), a novel generative model specifically designed for augmenting small, noisy datasets. We introduce a pipeline where data is augmented before regression model development and demonstrate that this consistently and significantly improves performance over other state-of-the-art tabular generative models. We apply this pipeline across six pharmaceutical datasets, and highlight its real-world applicability by developing novel polymers with medically desirable mucoadhesive properties, which we made and experimentally characterised. Additionally, we pre-train the model on the ChEMBL database of drug-like molecules, leveraging knowledge distillation to enhance its generalisability, making it readily available for use on pharmaceutical datasets containing small molecules, an extremely common pharmaceutical task. W

Controlling the size of powder particles is pivotal in the design of many pharmaceutical forms and the related manufacturing processes and plants. One of the most common techniques for particle size reduction in process industry is powder milling, whose efficiency relates to the mechanical properties of powder particles themselves. In this work, we first characterize the elastic and plastic response of different pharmaceutical powders by measuring their Young modulus, the hardness and the brittleness index via nano-indentation. Subsequently, we analyze the behavior of those powder samples during comminution via jet-mill at different process conditions. Finally, the correlation between single particle mechanical properties and milling process results is illustrated; the possibility to build a predictive model for powder grindability, based on nano-indentation data, is critically discussed

The digital transformation of pharmaceutical industry is a challenging task due to the high complexity of involved elements and the strict regulatory compliance. Maintenance activities in the pharmaceutical industry play an essential role in ensuring product quality and integral functioning of equipment and premises. This paper first identifies the key challenges of digitalization in pharmaceutical industry and creates the corresponding problem space for key involved elements. A literature review is conducted to investigate the mainstream maintenance strategies, digitalization models, tools and official guidance from authorities in pharmaceutical industry. Based on the review result, a semantic-driven digitalization framework is proposed aiming to improve the digital continuity and cohesion of digital resources and technologies for maintenance activities in the pharmaceutical industry. A case study is conducted to verify the feasibility of the proposed framework based on the water sampling activities in Merck Serono facility in Switzerland. A tool-chain is presented to enable the functional modules of the framework. Some of the key functional modules within the framework are implem

This document offers a critical overview of the emerging trends and significant advancements in artificial intelligence (AI) within the pharmaceutical industry. Detailing its application across key operational areas, including research and development, animal testing, clinical trials, hospital clinical stages, production, regulatory affairs, quality control and other supporting areas, the paper categorically examines AI's role in each sector. Special emphasis is placed on cutting-edge AI technologies like machine learning algorithms and their contributions to various aspects of pharmaceutical operations. Through this comprehensive analysis, the paper highlights the transformative potential of AI in reshaping the pharmaceutical industry's future.

The advent of 3D printing has transformed the pharmaceutical industry, enabling precision drug manufacturing with controlled release profiles, dosing, and structural complexity. Additive manufacturing (AM) addresses the growing demand for personalized medicine, overcoming limitations of traditional methods. This technology facilitates tailored dosage forms, complex geometries, and real-time quality control. Recent advancements in drop-on-demand printing, UV curable inks, material science, and regulatory frameworks are discussed. Despite opportunities for cost reduction, flexibility, and decentralized manufacturing, challenges persist in scalability, reproducibility, and regulatory adaptation. This review provides an in-depth analysis of the current state of AM in pharmaceutical manufacturing, exploring recent developments, challenges, and future directions for mainstream integration.

Pharmaceutical patents play an important role by protecting the innovation from copies but also drive researchers to innovate, create new products, and promote disruptive innovations focusing on collective health. The study of patent management usually refers to an exhaustive manual search. This happens, because patent documents are complex with a lot of details regarding the claims and methodology/results explanation of the invention. To mitigate the manual search, we proposed PATopics, a framework specially designed to extract relevant information for Pharmaceutical patents. PATopics is composed of four building blocks that extract textual information from the patents, build relevant topics that are capable of summarizing the patents, correlate these topics with useful patent characteristics and then, summarize the information in a friendly web interface to final users. The general contributions of PATopics are its ability to centralize patents and to manage patents into groups based on their similarities. We extensively analyzed the framework using 4,832 pharmaceutical patents concerning 809 molecules patented by 478 companies. In our analysis, we evaluate the use of the framewo

Pharmaceutical patents play a vital role in biochemical industries, especially in drug discovery, providing researchers with unique early access to data, experimental results, and research insights. With the advancement of machine learning, patent analysis has evolved from manual labor to tasks assisted by automatic tools. However, there still lacks an unified agent that assists every aspect of patent analysis, from patent reading to core chemical identification. Leveraging the capabilities of Large Language Models (LLMs) to understand requests and follow instructions, we introduce the $\textbf{first}$ intelligent agent in this domain, $\texttt{PatentAgent}$, poised to advance and potentially revolutionize the landscape of pharmaceutical research. $\texttt{PatentAgent}$ comprises three key end-to-end modules -- $\textit{PA-QA}$, $\textit{PA-Img2Mol}$, and $\textit{PA-CoreId}$ -- that respectively perform (1) patent question-answering, (2) image-to-molecular-structure conversion, and (3) core chemical structure identification, addressing the essential needs of scientists and practitioners in pharmaceutical patent analysis. Each module of $\texttt{PatentAgent}$ demonstrates significa

This research employs Gaussian Process Regression (GPR) with an ensemble kernel, integrating Exponential Squared, Revised Matérn, and Rational Quadratic kernels to analyze pharmaceutical sales data. Bayesian optimization was used to identify optimal kernel weights: 0.76 for Exponential Squared, 0.21 for Revised Matérn, and 0.13 for Rational Quadratic. The ensemble kernel demonstrated superior performance in predictive accuracy, achieving an \( R^2 \) score near 1.0, and significantly lower values in Mean Squared Error (MSE), Mean Absolute Error (MAE), and Root Mean Squared Error (RMSE). These findings highlight the efficacy of ensemble kernels in GPR for predictive analytics in complex pharmaceutical sales datasets.